Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maffezzoli Michele, Signori Alessio, Acunzo Alessandro, Buti Sebastiano, Bosoni Michela, Verzoni Elena, Di Marco Andrea, Lolli Cristian, Di Napoli Marilena, Fanelli Martina, Volta Alberto Dalla, Masini Cristina, Roviello Giandomenico, Iacovelli Roberto, Mennitto Alessia, Filippi Roberto, Sorarù Mariella, Formisano Luigi, Guida Annalisa, Fantinel Emanuela, Messina Carlo, Bonomi Lucia, Scagliarini Sarah, Nasso Cecilia, Chiellino Silvia, Maiorano Brigida Anna, Deppieri Filippo, Cavo Alessia, Conteduca Vincenza, Zai Silvia, Zucali Paolo Andrea, Tucci Marcello, Vignani Francesca, La Russa Francesca, Lombardo Laura, Caserta Claudia, Paolieri Federico, Bertolotti Francesca, Rescigno Pasquale, Banna Giuseppe Luigi, Fornarini Giuseppe, Bimbatti Davide, Rebuzzi Sara Elena
Аннотация
METHODS: The Meet-URO 33 study is a multicentre retrospective-prospective registry collecting real-world data on patients with mRCC. Multivariable logistic and Cox models were built for objective response rate (ORR), PFS and OS, with a propensity score (PS) adjustment for baseline imbalances.
RESULTS: Among 1497 patients, 755 were intermediate-risk (199 ICI-ICI, 556 ICI-TKI) and 312 poor-risk (77 ICI-ICI, 212 ICI-TKI). Median follow-up was 14.2 months (8.0 months and 14.5 months in poor- and intermediate-risk subgroups, respectively). In poor-risk patients, median OS was 20.3 versus 12.9 months (HR 0.87, 95% CI 0.59-1.28, p = 0.49), and median PFS was 6.7 versus 8.7 months (HR 1.10, 95% CI 0.79-1.54, p = 0.53), for ICI-ICI versus ICI-TKI, respectively. In the intermediate-risk patients treated with ICI-ICI versus ICI-TKI, median OS was 37.8 versus 35.5 months (HR 1.08; 95% CI 0.77-1.50; p = 0.65), and median PFS was 17.8 versus 18.6 months (HR 1.29, 95% CI 1.00-1.66, p = 0.050). ORR was 42.9% versus 45.8% in poor-risk patients (OR 0.72, 95% CI 0.39-1.34, p = 0.303) and 48.1% versus 54.3% in intermediate-risk patients (OR 0.71, 95% CI 0.48-1.04, p = 0.075).
CONCLUSIONS: No statistically significant differences in survival or response were observed between ICI-ICI and ICI-TKI combinations in patients with IMDC intermediate- and poor-risk mRCC.